Search Results - Mandjes, I.A.M.

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial

    Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial by Geurts, V.C.M., Voorwerk, L., Balduzzi, S., Salgado, R., Van de Vijver, K., van Dongen, M.G.J., Kemper, I., Mandjes, I.A.M., Heuver, M., Sparreboom, W., Haanen, J.B.A.G., Sonke, G.S., Horlings, H.M., Kok, M.

    Published in Breast (Edinburgh)
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

    Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response by Lips, E. H., Mulder, L., de Ronde, J. J., Mandjes, I. A. M., Koolen, B. B., Wessels, L. F. A., Rodenhuis, S., Wesseling, J.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

    Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004... by van Rossum, A.G.J., Kok, M., van Werkhoven, E., Opdam, M., Mandjes, I.A.M., van Leeuwen – Stok, A.E., van Tinteren, H., Imholz, A.L.T., Portielje, J.E.A., Bos, M.M.E.M., van Bochove, A., Wesseling, J., Rutgers, E.J., Linn, S.C., Oosterkamp, H.M.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics

    Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics by Lips, E. H., Mulder, L., de Ronde, J. J., Mandjes, I. A. M., Vincent, A., Vrancken Peeters, M. T. F. D., Nederlof, P. M., Wesseling, J., Rodenhuis, S.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    163MO Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial)

    163MO Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial) by Isaeva, O.I., Nederlof, I., de Graaf, M., Boeckx, B., Traets, J., Mandjes, I.A.M., Van De Vijver, K., Chelushkin, M., Drukker, C., Dongen, M.V., Sonke, G.S., Linn, S.C., Blank, C.U., de Visser, K.E., Salgado, R.F., Wessels, L.F.A., Schumacher, T.N., Horlings, H.M., Lambrechts, D., Kok, M.

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

    Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response by Lips, E.H, Mulder, L, de Ronde, J.J, Mandjes, I.A.M, Koolen, B.B, Wessels, L.F.A, Rodenhuis, S, Wesseling, J

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: